CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: HLA-DOA (ImmuneEditome ID:3111)

1. Gene summary of enriched editing regions for HLA-DOA

check button Gene summary
Gene informationGene symbol

HLA-DOA

Gene ID

3111

GeneSynonymsHLA-DNA|HLA-DZA|HLADZ
GeneCytomap

6p21.32

GeneTypeprotein-coding
GeneDescriptionHLA class II histocompatibility antigen, DO alpha chain|HLA-D0-alpha|MHC DN-alpha|MHC DZ alpha|MHC class II antigen DOA|lymphocyte antigen|major histocompatibility complex, class II, DN alpha
GeneModificationdate20230518
UniprotIDP06340;X5CF87;A0A1V0E3Q8;A0A1V0E3N1;A0A1V0E3Q5;A0A1V0E3M7;A0A1V0E3R3;A0A1V0E3S6;A0A1V0E3Q2;A0A1V0E3S7;A0A1V0E3T1;A0A1V0E3P6;F6WU08;A0A1V0E3P8;A0A1V0E3P1;A0A1V0E3P3;A0A1V0E3Q6;A0A1V0E3P9;A0A1V0E3R6;A0A1V0E3N7;A0A1V0E3S0;A0A1V0E3N3;A0A1V0E3Q1;A0A1V0E3P0;A0A1V0E3R4;A0A1V0E3R8;A0A1V0E3Q4;A0A1V0E3N6;A0A1V0E3R0;A0A1V0E3S4;A0A1V0E3Q7;A0A1V0E3Q3;A0A140T9P4;A0A140T9G1;A0A140T9J7;A0A140T8X4;A0A140T9G3;A0A140T9F9
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr6:33005201-33005903:-ENST00000229829.6ENSG00000204252.11HLA-DOAUTR3MER5B,AluSc,AluJrchr6:33005201-33005903:-.alignment


Top

2. Tumor-specific enriched editing regions for HLA-DOA


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr6:33005201-33005903:-BRCAEER2.3401e-10image
ENSG00000204252.11,HLA-DOABRCAEAG2.3401e-10image
chr6:33005201-33005903:-COADEER1.8117e-03image
ENSG00000204252.11,HLA-DOACOADEAG1.8117e-03image
chr6:33005201-33005903:-KIRCEER3.5559e-02image
ENSG00000204252.11,HLA-DOAKIRCEAG3.5559e-02image
chr6:33005201-33005903:-KIRPEER1.2441e-03image
ENSG00000204252.11,HLA-DOAKIRPEAG1.2441e-03image
chr6:33005201-33005903:-LUADEER1.3602e-14image
ENSG00000204252.11,HLA-DOALUADEAG1.3602e-14image
chr6:33005201-33005903:-LUSCEER3.8739e-18image
ENSG00000204252.11,HLA-DOALUSCEAG3.8739e-18image
chr6:33005201-33005903:-PRADEER3.3025e-02image
ENSG00000204252.11,HLA-DOAPRADEAG3.3025e-02image
chr6:33005201-33005903:-UCECEER1.0659e-03image
ENSG00000204252.11,HLA-DOAUCECEAG1.0659e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr6:33005201-33005903:-KIRCPathEER1.6765e-021.0789e-020.1122image
ENSG00000204252.11,HLA-DOAKIRCPathEAG1.6765e-021.0789e-020.1122image
chr6:33005201-33005903:-KIRPPathEER1.8917e-024.8812e-020.1318image
ENSG00000204252.11,HLA-DOAKIRPPathEAG1.8917e-024.8812e-020.1318image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for HLA-DOA


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:33005201-33005903:-DLBCEERENSG00000157379,DHRS10.63706.2419e-031.3532e-050.5833imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr6:33005201-33005903:-DLBCEERENSG00000149743,TRPT10.56902.6386e-021.6428e-040.5177imageNNNAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr6:33005201-33005903:-DLBCEERENSG00000142166,IFNAR1-0.56052.6864e-021.8083e-03-0.4388imageNNIFNAR1Macrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr6:33005201-33005903:-DLBCEERENSG00000049249,TNFRSF9-0.56392.8697e-026.8973e-04-0.4728imageNNTNFRSF9Macrophages_M2GSVA_HALLMARK_HEME_METABOLISM
chr6:33005201-33005903:-DLBCEERENSG00000248275,TRIM52-AS10.52023.4026e-021.4036e-050.5825imageNNNAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr6:33005201-33005903:-DLBCEERENSG00000089820,ARHGAP40.54633.6076e-026.5587e-040.4745imageNNARHGAP4T_cells_CD4_memory_activatedGSVA_HALLMARK_ANDROGEN_RESPONSE
chr6:33005201-33005903:-DLBCEERENSG00000186665,C17orf58-0.54754.0545e-024.7514e-04-0.4851imageNNNAB_cells_naiveGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr6:33005201-33005903:-DLBCEERENSG00000237976,RP11-126K1.60.53294.5644e-023.5669e-060.6134imageNNNAMacrophages_M1GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr6:33005201-33005903:-DLBCEERENSG00000171522,PTGER4-0.52224.8349e-021.9399e-03-0.4362imageNNPTGER4Macrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr6:33005201-33005903:-DLBCEERENSG00000269609,RPARP-AS10.52874.8466e-022.3193e-050.5703imageNNNAMast_cells_activatedGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for HLA-DOA


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr6:33005201-33005903:-
TGCTEERA3ENSG00000168488.14chr1628835932:28836176:28836750:28836847:28836727:28836847-0.27141.4558e-022.3580e-05-0.4018imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000204252.11,HLA-DOA
TGCTEAGA3ENSG00000168488.14chr1628835932:28836176:28836750:28836847:28836727:28836847-0.27141.3350e-022.3580e-05-0.4018imageNADAR;DGCR8;DKC1;ELAVL1;EWSR1;FBL;FUS;HNRNPA1;IGF2BP1;IGF2BP3;LIN28;LIN28A;NOP58;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYC_TARGETS_V1

More results



Top

5. Enriched editing regions and immune infiltration for HLA-DOA


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr6:33005201-33005903:-ACCEERNK_cells_resting3.7537e-020.3949image
ENSG00000204252.11,HLA-DOAACCEAGNK_cells_resting3.7537e-020.3949image
chr6:33005201-33005903:-BLCAEERMacrophages_M23.6055e-030.1789image
ENSG00000204252.11,HLA-DOABLCAEAGMacrophages_M23.6055e-030.1789image
chr6:33005201-33005903:-BRCAEERB_cells_naive1.6901e-07-0.1649image
ENSG00000204252.11,HLA-DOABRCAEAGB_cells_naive1.6901e-07-0.1649image
chr6:33005201-33005903:-CESCEERNeutrophils6.5848e-070.3352image
ENSG00000204252.11,HLA-DOACESCEAGNeutrophils6.5848e-070.3352image
chr6:33005201-33005903:-CHOLEERNK_cells_activated5.2114e-040.6228image
ENSG00000204252.11,HLA-DOACHOLEAGNK_cells_activated5.2114e-040.6228image
chr6:33005201-33005903:-COADEERDendritic_cells_activated1.4078e-040.3099image
ENSG00000204252.11,HLA-DOACOADEAGDendritic_cells_activated1.4078e-040.3099image
chr6:33005201-33005903:-DLBCEERMacrophages_M18.8357e-03-0.3740image
ENSG00000204252.11,HLA-DOADLBCEAGMacrophages_M18.8357e-03-0.3740image
chr6:33005201-33005903:-ESCAEERMacrophages_M06.0903e-030.2554image
ENSG00000204252.11,HLA-DOAESCAEAGMacrophages_M06.0903e-030.2554image
chr6:33005201-33005903:-GBMEERT_cells_CD4_naive8.1947e-040.2612image
ENSG00000204252.11,HLA-DOAGBMEAGT_cells_CD4_naive8.1947e-040.2612image
chr6:33005201-33005903:-HNSCEERMacrophages_M28.3800e-050.2114image
ENSG00000204252.11,HLA-DOAHNSCEAGMacrophages_M28.3800e-050.2114image
chr6:33005201-33005903:-KICHEERDendritic_cells_activated1.2134e-020.3593image
ENSG00000204252.11,HLA-DOAKICHEAGDendritic_cells_activated1.2134e-020.3593image
chr6:33005201-33005903:-KIRCEERMacrophages_M23.3068e-03-0.1513image
ENSG00000204252.11,HLA-DOAKIRCEAGMacrophages_M23.3068e-03-0.1513image
chr6:33005201-33005903:-KIRPEERDendritic_cells_activated4.0286e-050.2576image
ENSG00000204252.11,HLA-DOAKIRPEAGDendritic_cells_activated4.0286e-050.2576image
ENSG00000204252.11,HLA-DOALAMLEAGNK_cells_activated3.6528e-020.2372image
chr6:33005201-33005903:-LGGEERT_cells_regulatory_(Tregs)1.6634e-02-0.1270image
ENSG00000204252.11,HLA-DOALGGEAGT_cells_regulatory_(Tregs)1.6634e-02-0.1270image
chr6:33005201-33005903:-LIHCEERMast_cells_resting3.1706e-040.2820image
ENSG00000204252.11,HLA-DOALIHCEAGMast_cells_resting3.1706e-040.2820image
chr6:33005201-33005903:-LUADEERDendritic_cells_resting2.7042e-05-0.1882image
ENSG00000204252.11,HLA-DOALUADEAGDendritic_cells_resting2.7042e-05-0.1882image
chr6:33005201-33005903:-LUSCEERMast_cells_resting3.7340e-04-0.1698image
ENSG00000204252.11,HLA-DOALUSCEAGMast_cells_resting3.7340e-04-0.1698image
chr6:33005201-33005903:-MESOEERDendritic_cells_activated1.3595e-020.2820image
ENSG00000204252.11,HLA-DOAMESOEAGDendritic_cells_activated1.3595e-020.2820image
chr6:33005201-33005903:-OVEERB_cells_memory7.9947e-040.2083image
ENSG00000204252.11,HLA-DOAOVEAGB_cells_memory7.9947e-040.2083image
chr6:33005201-33005903:-PAADEERT_cells_CD83.8768e-03-0.2250image
ENSG00000204252.11,HLA-DOAPAADEAGT_cells_CD83.8768e-03-0.2250image
chr6:33005201-33005903:-PRADEERDendritic_cells_resting7.1306e-04-0.1643image
ENSG00000204252.11,HLA-DOAPRADEAGDendritic_cells_resting7.1306e-04-0.1643image
chr6:33005201-33005903:-SARCEERDendritic_cells_activated8.7768e-030.1844image
ENSG00000204252.11,HLA-DOASARCEAGDendritic_cells_activated8.7768e-030.1844image
chr6:33005201-33005903:-SKCMEERB_cells_naive1.8829e-05-0.2219image
ENSG00000204252.11,HLA-DOASKCMEAGB_cells_naive1.8829e-05-0.2219image
chr6:33005201-33005903:-STADEERMast_cells_activated1.6029e-030.1791image
ENSG00000204252.11,HLA-DOASTADEAGMast_cells_activated1.6029e-030.1791image
chr6:33005201-33005903:-TGCTEERT_cells_regulatory_(Tregs)2.8133e-04-0.3004image
ENSG00000204252.11,HLA-DOATGCTEAGT_cells_regulatory_(Tregs)2.8133e-04-0.3004image
chr6:33005201-33005903:-THCAEERMast_cells_resting1.7637e-080.2737image
ENSG00000204252.11,HLA-DOATHCAEAGMast_cells_resting1.7637e-080.2737image
chr6:33005201-33005903:-UCSEERMast_cells_resting4.1134e-020.2991image
ENSG00000204252.11,HLA-DOAUCSEAGMast_cells_resting4.1134e-020.2991image
chr6:33005201-33005903:-UVMEERT_cells_follicular_helper2.8842e-03-0.5926image
ENSG00000204252.11,HLA-DOAUVMEAGT_cells_follicular_helper2.8842e-03-0.5926image


Top

6. Enriched editing regions and immune gene sets for HLA-DOA


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr6:33005201-33005903:-BRCAEER1.3660e-04image2.6161e-06-0.1483image
ENSG00000204252.11,HLA-DOABRCAEAG1.3660e-04image2.6161e-06-0.1483image
chr6:33005201-33005903:-LUSCEER1.1133e-02image4.2737e-02-0.0972image
ENSG00000204252.11,HLA-DOALUSCEAG1.1133e-02image4.2737e-02-0.0972image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000204252.11,HLA-DOAPAADEAG8.3065e-040.25938.0103e-030.20701.5954e-030.24541.6420e-020.1877image
chr6:33005201-33005903:-PAADEER8.3065e-040.25938.0103e-030.20701.5954e-030.24541.6420e-020.1877image
ENSG00000204252.11,HLA-DOATHCAEAG1.1980e-02-0.12407.8747e-03-0.13111.4107e-02-0.12116.7268e-04-0.1673image
chr6:33005201-33005903:-THCAEER1.1980e-02-0.12407.8747e-03-0.13111.4107e-02-0.12116.7268e-04-0.1673image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000204252.11,HLA-DOAACCGSVA_HALLMARK_MYC_TARGETS_V2EAG2.1008e-020.4341image
chr6:33005201-33005903:-ACCGSVA_HALLMARK_MYC_TARGETS_V2EER2.1008e-020.4341image
chr6:33005201-33005903:-BLCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.3458e-03-0.1868image
ENSG00000204252.11,HLA-DOABLCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.3458e-03-0.1868image
ENSG00000204252.11,HLA-DOABRCAGSVA_HALLMARK_KRAS_SIGNALING_UPEAG7.1346e-24-0.3118image
chr6:33005201-33005903:-BRCAGSVA_HALLMARK_KRAS_SIGNALING_UPEER7.1346e-24-0.3118image
chr6:33005201-33005903:-CESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.7855e-04-0.2430image
ENSG00000204252.11,HLA-DOACESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.7855e-04-0.2430image
chr6:33005201-33005903:-COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.3225e-05-0.3520image
ENSG00000204252.11,HLA-DOACOADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3225e-05-0.3520image
ENSG00000204252.11,HLA-DOADLBCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG4.7142e-04-0.4853image
chr6:33005201-33005903:-DLBCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER4.7142e-04-0.4853image
ENSG00000204252.11,HLA-DOAESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.0112e-02-0.2400image
chr6:33005201-33005903:-ESCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.0112e-02-0.2400image
ENSG00000204252.11,HLA-DOAGBMGSVA_HALLMARK_COMPLEMENTEAG5.9346e-08-0.4114image
chr6:33005201-33005903:-GBMGSVA_HALLMARK_COMPLEMENTEER5.9346e-08-0.4114image
chr6:33005201-33005903:-HNSCGSVA_HALLMARK_GLYCOLYSISEER5.2547e-070.2677image
ENSG00000204252.11,HLA-DOAHNSCGSVA_HALLMARK_GLYCOLYSISEAG5.2547e-070.2677image
ENSG00000204252.11,HLA-DOAKICHGSVA_HALLMARK_ANGIOGENESISEAG1.6517e-02-0.3444image
chr6:33005201-33005903:-KICHGSVA_HALLMARK_ANGIOGENESISEER1.6517e-02-0.3444image
ENSG00000204252.11,HLA-DOAKIRCGSVA_HALLMARK_HEME_METABOLISMEAG3.1363e-02-0.1112image
chr6:33005201-33005903:-KIRCGSVA_HALLMARK_HEME_METABOLISMEER3.1363e-02-0.1112image
ENSG00000204252.11,HLA-DOAKIRPGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.3541e-05-0.2650image
chr6:33005201-33005903:-KIRPGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.3541e-05-0.2650image
ENSG00000204252.11,HLA-DOALGGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.3434e-05-0.2059image
chr6:33005201-33005903:-LGGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER9.3434e-05-0.2059image
chr6:33005201-33005903:-LIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.5974e-06-0.3628image
ENSG00000204252.11,HLA-DOALIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.5974e-06-0.3628image
ENSG00000204252.11,HLA-DOALUADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.5039e-08-0.2380image
chr6:33005201-33005903:-LUADGSVA_HALLMARK_BILE_ACID_METABOLISMEER9.5039e-08-0.2380image
ENSG00000204252.11,HLA-DOALUSCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG3.0508e-07-0.2425image
chr6:33005201-33005903:-LUSCGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER3.0508e-07-0.2425image
chr6:33005201-33005903:-MESOGSVA_HALLMARK_P53_PATHWAYEER6.1667e-030.3115image
ENSG00000204252.11,HLA-DOAMESOGSVA_HALLMARK_P53_PATHWAYEAG6.1667e-030.3115image
chr6:33005201-33005903:-OVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.4550e-03-0.1885image
ENSG00000204252.11,HLA-DOAOVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.4550e-03-0.1885image
chr6:33005201-33005903:-PAADGSVA_HALLMARK_P53_PATHWAYEER3.0408e-040.2794image
ENSG00000204252.11,HLA-DOAPAADGSVA_HALLMARK_P53_PATHWAYEAG3.0408e-040.2794image
chr6:33005201-33005903:-PRADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.5295e-13-0.3465image
ENSG00000204252.11,HLA-DOAPRADGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.5295e-13-0.3465image
chr6:33005201-33005903:-READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.0832e-020.2915image
ENSG00000204252.11,HLA-DOAREADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.0832e-020.2915image
ENSG00000204252.11,HLA-DOASKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG5.4394e-09-0.2993image
chr6:33005201-33005903:-SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER5.4394e-09-0.2993image
ENSG00000204252.11,HLA-DOASTADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.9584e-08-0.3094image
chr6:33005201-33005903:-STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.9584e-08-0.3094image
chr6:33005201-33005903:-TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.7821e-03-0.2355image
ENSG00000204252.11,HLA-DOATGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.7821e-03-0.2355image
chr6:33005201-33005903:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.4054e-13-0.3512image
ENSG00000204252.11,HLA-DOATHCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.4054e-13-0.3512image
chr6:33005201-33005903:-THYMGSVA_HALLMARK_APICAL_SURFACEEER1.5754e-02-0.2459image
ENSG00000204252.11,HLA-DOATHYMGSVA_HALLMARK_APICAL_SURFACEEAG1.5754e-02-0.2459image
ENSG00000204252.11,HLA-DOAUCECGSVA_HALLMARK_APICAL_SURFACEEAG2.1371e-02-0.2203image
chr6:33005201-33005903:-UCECGSVA_HALLMARK_APICAL_SURFACEEER2.1371e-02-0.2203image
ENSG00000204252.11,HLA-DOAUCSGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.2605e-030.4006image
chr6:33005201-33005903:-UCSGSVA_HALLMARK_FATTY_ACID_METABOLISMEER5.2605e-030.4006image
chr6:33005201-33005903:-UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER8.1994e-04-0.6484image
ENSG00000204252.11,HLA-DOAUVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.1994e-04-0.6484image


Top

7. Enriched editing regions and drugs for HLA-DOA


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000204252.11,HLA-DOAACCBAY.61.3606EAG3.3697e-02-0.4025image
chr6:33005201-33005903:-ACCBAY.61.3606EER3.3697e-02-0.4025image
chr6:33005201-33005903:-BLCACCT018159EER3.6413e-03-0.1787image
ENSG00000204252.11,HLA-DOABLCACCT018159EAG3.6413e-03-0.1787image
ENSG00000204252.11,HLA-DOABRCAAZD6244EAG7.5416e-130.2246image
chr6:33005201-33005903:-BRCAAZD6244EER7.5416e-130.2246image
chr6:33005201-33005903:-CESCCisplatinEER5.9830e-030.1891image
ENSG00000204252.11,HLA-DOACESCCisplatinEAG5.9830e-030.1891image
chr6:33005201-33005903:-CHOLFH535EER1.1408e-02-0.4794image
ENSG00000204252.11,HLA-DOACHOLFH535EAG1.1408e-02-0.4794image
chr6:33005201-33005903:-COADGW843682XEER9.2521e-070.3930image
ENSG00000204252.11,HLA-DOACOADGW843682XEAG9.2521e-070.3930image
ENSG00000204252.11,HLA-DOADLBCBosutinibEAG3.8603e-03-0.4136image
chr6:33005201-33005903:-DLBCBosutinibEER3.8603e-03-0.4136image
chr6:33005201-33005903:-ESCABryostatin.1EER2.7085e-03-0.2784image
ENSG00000204252.11,HLA-DOAESCABryostatin.1EAG2.7085e-03-0.2784image
chr6:33005201-33005903:-GBMIPA.3EER1.2882e-08-0.4297image
ENSG00000204252.11,HLA-DOAGBMIPA.3EAG1.2882e-08-0.4297image
ENSG00000204252.11,HLA-DOAHNSCBicalutamideEAG6.2702e-06-0.2419image
chr6:33005201-33005903:-HNSCBicalutamideEER6.2702e-06-0.2419image
chr6:33005201-33005903:-KICHCyclopamineEER4.8078e-02-0.2868image
ENSG00000204252.11,HLA-DOAKICHCyclopamineEAG4.8078e-02-0.2868image
ENSG00000204252.11,HLA-DOAKIRCCyclopamineEAG2.9826e-05-0.2144image
chr6:33005201-33005903:-KIRCCyclopamineEER2.9826e-05-0.2144image
ENSG00000204252.11,HLA-DOAKIRPA.443654EAG7.2210e-05-0.2493image
chr6:33005201-33005903:-KIRPA.443654EER7.2210e-05-0.2493image
ENSG00000204252.11,HLA-DOALAMLCisplatinEAG1.9321e-02-0.2644image
chr6:33005201-33005903:-LGGGW.441756EER2.3374e-04-0.1941image
ENSG00000204252.11,HLA-DOALGGGW.441756EAG2.3374e-04-0.1941image
chr6:33005201-33005903:-LIHCBIRB.0796EER3.2029e-030.2324image
ENSG00000204252.11,HLA-DOALIHCBIRB.0796EAG3.2029e-030.2324image
ENSG00000204252.11,HLA-DOALUADAS601245EAG1.1195e-090.2705image
chr6:33005201-33005903:-LUADAS601245EER1.1195e-090.2705image
ENSG00000204252.11,HLA-DOALUSCAS601245EAG1.3155e-080.2683image
chr6:33005201-33005903:-LUSCAS601245EER1.3155e-080.2683image
ENSG00000204252.11,HLA-DOAMESOFH535EAG2.5804e-020.2557image
chr6:33005201-33005903:-MESOFH535EER2.5804e-020.2557image
chr6:33005201-33005903:-OVGDC0941EER9.3621e-060.2730image
ENSG00000204252.11,HLA-DOAOVGDC0941EAG9.3621e-060.2730image
chr6:33005201-33005903:-PAADAZD6482EER1.4880e-050.3391image
ENSG00000204252.11,HLA-DOAPAADAZD6482EAG1.4880e-050.3391image
ENSG00000204252.11,HLA-DOAPCPGMethotrexateEAG4.9837e-020.2122image
chr6:33005201-33005903:-PCPGMethotrexateEER4.9837e-020.2122image
chr6:33005201-33005903:-PRADMethotrexateEER1.4641e-040.1847image
ENSG00000204252.11,HLA-DOAPRADMethotrexateEAG1.4641e-040.1847image
chr6:33005201-33005903:-READAS601245EER1.8825e-020.3158image
ENSG00000204252.11,HLA-DOAREADAS601245EAG1.8825e-020.3158image
chr6:33005201-33005903:-SARCEmbelinEER2.0149e-020.1638image
ENSG00000204252.11,HLA-DOASARCEmbelinEAG2.0149e-020.1638image
ENSG00000204252.11,HLA-DOASKCMDMOGEAG4.6028e-060.2372image
chr6:33005201-33005903:-SKCMDMOGEER4.6028e-060.2372image
chr6:33005201-33005903:-STADAZD7762EER1.4934e-080.3156image
ENSG00000204252.11,HLA-DOASTADAZD7762EAG1.4934e-080.3156image
chr6:33005201-33005903:-TGCTAZD6482EER6.2465e-050.3294image
ENSG00000204252.11,HLA-DOATGCTAZD6482EAG6.2465e-050.3294image
chr6:33005201-33005903:-THCACGP.60474EER9.8545e-070.2389image
ENSG00000204252.11,HLA-DOATHCACGP.60474EAG9.8545e-070.2389image
ENSG00000204252.11,HLA-DOATHYMCyclopamineEAG5.2203e-03-0.2829image
chr6:33005201-33005903:-THYMCyclopamineEER5.2203e-03-0.2829image
chr6:33005201-33005903:-UCSA.770041EER5.2917e-03-0.4004image
ENSG00000204252.11,HLA-DOAUCSA.770041EAG5.2917e-03-0.4004image
chr6:33005201-33005903:-UVMGSK269962AEER8.9468e-04-0.6448image
ENSG00000204252.11,HLA-DOAUVMGSK269962AEAG8.9468e-04-0.6448image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType